Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017091952) USE OF AKT2 IN DIAGNOSIS AND TREATMENT OF TUMOR
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/091952 International Application No.: PCT/CN2015/096011
Publication Date: 08.06.2017 International Filing Date: 30.11.2015
Chapter 2 Demand Filed: 21.08.2017
IPC:
A61K 31/519 (2006.01) ,A61K 31/52 (2006.01) ,A61K 45/00 (2006.01) ,A61K 45/06 (2006.01) ,A61K 49/00 (2006.01) ,A61P 35/00 (2006.01) ,A61P 35/02 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
52
Purines, e.g. adenine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
49
Preparations for testing in vivo
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
Applicants:
谢彦晖 XIE, Yanhui [CN/CN]; CN
Inventors:
谢彦晖 XIE, Yanhui; CN
谢咪雪 XIE, Mixue; CN
Agent:
北京永新同创知识产权代理有限公司 NTD UNIVATION INTELLECTUAL PROPERTY AGENCY LTD.; 中国北京市 西城区金融大街27号投资广场A座1802 Room 1802, 18th Floor, Block A, Investment Plaza 27 Jinrongdajie, Xicheng District Beijing 100033, CN
Priority Data:
Title (EN) USE OF AKT2 IN DIAGNOSIS AND TREATMENT OF TUMOR
(FR) UTILISATION DE L'AKT2 DANS LE DIAGNOSTIC ET LE TRAITEMENT D'UNE TUMEUR
(ZH) AKT2在诊断和治疗肿瘤中的用途
Abstract:
(EN) Provided is a use of a pharmaceutical composition in treating a glucocorticoid-resistant tumor characterized by an increased level of AKT2 expression. The pharmaceutical composition comprises an Akt2 inhibitor, a glucocorticoid, any existing pharmaceutically acceptable carrier, an excipient and/or a diluent. Also provided are a use of an Akt2 detection agent in detecting a glucocorticoid-resistant tumor, and a use of an Akt2 inhibitor in preparation of a pharmaceutical composition for treating a tumor.
(FR) La présente invention concerne l'utilisation d'une composition pharmaceutique pour traiter une tumeur résistante aux glucocorticoïdes caractérisée par un niveau accru d'expression de l'AKT2. La composition pharmaceutique comprend un inhibiteur de l'Akt2, un glucocorticoïde, n'importe quel véhicule pharmaceutiquement acceptable, un excipient et/ou un diluant. L'invention concerne également l'utilisation d'un agent de détection de l'Akt2 pour détecter une tumeur résistante aux glucocorticoïdes ainsi que l'utilisation d'un inhibiteur de l'Akt2 dans la préparation d'une composition pharmaceutique pour le traitement d'une tumeur.
(ZH) 治疗特征为Akt2表达升高的糖皮质激素耐药肿瘤的药物组合物,其包含Akt2抑制剂和糖皮质激素以及任选存在的药物可接受的载体、赋形剂和/或稀释剂;Akt2检测剂在检测糖皮质激素耐药肿瘤中的用途;Akt2抑制剂在制备用于治疗肿瘤的药物组合物中的用途。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)
Also published as:
CN108472296EP3375445